Skip to Content

BioLine Rx Ltd ADR BLRX Stock Quote

| Rating as of


Last close prices updated as of Jun 07, 2023, 4:25 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 1.60
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Small Value
  • Day Range 1.58  –  1.65
  • Year Range 0.55  –  1.98
  • Market Cap 99.6796 Mil
  • Volume / Avg 252,943.0 /  502,831.7
  • Price / Sales
  • Price / Book 2.52
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis BLRX

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics BLRX

Company Profile BLRX

Business Description

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

2 HaMa’ayan Street
Modi’in, 7177871, ISR
Industry Biotechnology
Employees 49

Competitors & Peers BLRX

Morningstar does not cover competitors or peers for this firm.

FAQs for BioLine Rx Ltd ADR Stock

No. BLRX does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

BLRX’s market cap is 99.68 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

BLRX’s stock style is Small Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

BLRX’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare BLRX’s historical performance against its industry peers and the overall market.